Study seeks more targeted treatment for hypertrophic cardiomyopathy

15th May 2015

An international study looking at improving the treatment of people with hypertrophic cardiomyopathy has spread to more centres.

The study, called the HCM Registry, is providing patients with a detailed assessment and following them up for five years.  The research aims to help doctors predict which patients are likely to develop complications and so give more targeted treatment.

A total of 34 medical centres around the globe are now taking part in the research and 160 patients have already been enrolled in the UK, though more are needed.

The study’s co-chief investigator Professor Stefan Neubauer said: “The study is designed to improve the ability of doctors to predict which patients are likely to develop complications, and based on that, to improve treatment.”

Assessment of patients will use sophisticated tests, including MRI, genetic testing and testing biomarkers (natural substances in the blood which indicate heart muscle stress, damage and scarring).

The research, funded by the National Institutes of Health, is being organised by the University of Oxford and the University of Virginia in America. The study wants 2,750 people with HCM enrolled in the next few months.

The centres in the UK, other than Oxford, are  now the Universities of Glasgow and Aberdeen, University Hospitals Birmingham, Royal Infirmary of Edinburgh,  University of Leeds, Glenfield Hospital (Leicester), and four hospitals in London – the Chest Hospital, Kings College St Thomas’, Royal Brompton Hospital and St George’s.

For further information about the study, see the study website or email research fellow Dr Masliza Mahmod.